Palvella Therapeutics (PVLA) to Release Quarterly Earnings on Tuesday

Palvella Therapeutics (NASDAQ:PVLA) is expected to release its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Palvella Therapeutics to post earnings of ($0.95) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 8:30 AM ET.

Palvella Therapeutics Price Performance

Shares of NASDAQ PVLA opened at $112.37 on Monday. The firm has a 50-day simple moving average of $104.52 and a 200-day simple moving average of $90.80. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -42.73 and a beta of -0.31. Palvella Therapeutics has a 52 week low of $18.23 and a 52 week high of $151.18.

Wall Street Analysts Forecast Growth

PVLA has been the topic of several research reports. Oppenheimer restated an “outperform” rating and set a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. Canaccord Genuity Group increased their price objective on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. BTIG Research raised their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Finally, TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $195.93.

Insider Activity at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Elaine J. Heron bought 2,400 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the acquisition, the director directly owned 47,812 shares in the company, valued at $5,976,500. The trade was a 5.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is currently owned by insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Group One Trading LLC boosted its position in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Palvella Therapeutics in the 3rd quarter valued at $36,000. JPMorgan Chase & Co. raised its holdings in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Palvella Therapeutics during the 2nd quarter worth about $85,000. Finally, BNP Paribas Financial Markets acquired a new position in Palvella Therapeutics during the 2nd quarter worth about $104,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.